Artificial Intelligence–Powered Assessment of Pathologic Response to Neoadjuvant Atezolizumab in Patients With NSCLC: Results From the LCMC3 Study-Reference-Cited by-同舟云学术

Artificial Intelligence–Powered Assessment of Pathologic Response to Neoadjuvant Atezolizumab in Patients With NSCLC: Results From the LCMC3 Study

Published:2023-12 Issue: Volume: Page:
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Dacic Sanja,Travis William D.,Giltnane Jennifer M.,Kos Filip,Abel John,Hilz Stephanie,Fujimoto Junya,Sholl Lynette,Ritter Jon,Khalil Farah,Liu Yi,Taylor-Weiner Amaro,Resnick Murray,Yu Hui,Hirsch Fred R.,Bunn Paul A.,Carbone David P.,Rusch Valerie,Kwiatkowski David J.,Johnson Bruce E.,Lee Jay M.,Hennek Stephanie R.,Wapinski Ilan,Nicholas Alan,Johnson Ann,Schulze Katja,Kris Mark G.,Wistuba Ignacio I.

Funder

Genentech

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference30 articles.

1. Pembrolizumab for early triple-negative breast cancer;Schmid;N Engl J Med,2020

2. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer;Forde;N Engl J Med,2022

3. Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint;Hellmann;Lancet Oncol,2014

4. Evaluation of pathologic complete response as a surrogate for long-term survival outcomes in triple-negative breast cancer;Huang;J Natl Compr Canc Netw,2020

5. Evaluation of pathological complete response as surrogate endpoint in neoadjuvant randomised clinical trials of early stage breast cancer: systematic review and meta-analysis;Conforti;Br Med J,2021

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Five-year follow-up of neoadjuvant PD-1 inhibitor (sintilimab) in non-small cell lung cancer;Journal for ImmunoTherapy of Cancer;2024-08

2. Artificial Intelligence Enhances NSCLC Care by Predicting Treatment Outcomes, Validating Neoadjuvant Therapies, and Improving Precision;Journal of Thoracic Oncology;2024-05

3. Pathology of Surgically Resected Lung Cancers Following Neoadjuvant Therapy;Advances in Anatomic Pathology;2024-04-09

4. Lung Cancer Surgery in Octogenarians: Implications and Advantages of Artificial Intelligence in the Preoperative Assessment;Healthcare;2024-04-07